Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ibio Inc (IBIO)

Ibio Inc (IBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,691
  • Shares Outstanding, K 9,149
  • Annual Sales, $ 230 K
  • Annual Income, $ -24,910 K
  • EBIT $ -17 M
  • EBITDA $ -15 M
  • 60-Month Beta -3.24
  • Price/Sales 98.41
  • Price/Cash Flow N/A
  • Price/Book 1.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.45
  • Number of Estimates 1
  • High Estimate -0.45
  • Low Estimate -0.45
  • Prior Year -2.42
  • Growth Rate Est. (year over year) +81.40%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.19 +13.24%
on 11/21/24
2.97 -16.50%
on 12/02/24
+0.29 (+13.24%)
since 11/20/24
3-Month
1.80 +37.78%
on 09/24/24
3.15 -21.27%
on 10/22/24
+0.51 (+25.89%)
since 09/20/24
52-Week
1.02 +142.80%
on 01/18/24
4.98 -50.20%
on 03/28/24
+1.09 (+78.42%)
since 12/20/23

Most Recent Stories

More News
iBio Strengthens Board with Appointment of Two New Independent Directors

IBIO : 2.48 (+2.48%)
iBio Reports Fiscal First Quarter 2025 Financial Results

IBIO : 2.48 (+2.48%)
Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching

Less stringent requirements in pharmaceuticals and biotechnology could help biotechs by prompting accelerated drug approvals.

SRNE : 0.0008 (-33.33%)
TNXP : 0.6116 (+7.30%)
IBB : 132.73 (+1.16%)
JAGX : 0.9255 (+6.00%)
NVAX : 8.70 (+0.23%)
INO : 1.8400 (-0.27%)
GILD : 92.57 (+1.62%)
MRNA : 39.39 (-0.43%)
VXRT : 0.6196 (+2.70%)
IBIO : 2.48 (+2.48%)
XBI : 91.28 (+1.64%)
PFE : 26.36 (+2.29%)
iBio and AstralBio Provide Update on Myostatin Program for Obesity

IBIO : 2.48 (+2.48%)
Pre-Market Brief: Stocks Slide As Growth Fears Deepen

December S&P 500 futures (ESZ22) are trending down -0.16% this morning after three major US benchmark indices finished the regular session in the red as market participants fretted over Federal Reserve...

ESZ22 : 3,871.47s (-0.66%)
META : 585.25 (-1.73%)
BAC : 44.17 (+1.82%)
JPM : 237.60 (+1.99%)
MDB : 245.63 (+0.26%)
MMAT : 0.5258 (-17.84%)
SWBI : 10.04 (-1.47%)
IBIO : 2.48 (+2.48%)
ABNB : 134.21 (+3.76%)
Pre-Market Brief: Stocks Plunge On Mounting Recession Risks

December S&P 500 futures (ESZ22) are trending down -0.68% this morning after the Dow Jones Industrial Average and S&P 500 index continued to fall deeper into bear-market territory as investors digested...

ESZ22 : 3,871.47s (-0.66%)
BIIB : 146.47 (-0.62%)
RUM : 7.19 (-1.10%)
MNMD : 7.16 (+2.07%)
SAND : 5.39 (+0.56%)
IBIO : 2.48 (+2.48%)
iBio (IBIO) Q3 2022 Earnings Call Transcript

IBIO earnings call for the period ending March 31, 2022.

IBIO : 2.48 (+2.48%)
iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update

BRYAN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and...

IBIO : 2.48 (+2.48%)
iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022

BRYAN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and...

IBIO : 2.48 (+2.48%)
iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference

BRYAN, Texas, March 11, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and...

IBIO : 2.48 (+2.48%)

Business Summary

Ibio Inc., formerly known as iBioPharma Inc., is a biopharmaceutical company that primarily focuses on developing vaccines and therapeutic proteins based upon its plant-based iBioLaunch platform technology. The Company's hydroponically grown green plants can be used for the development and manufacture...

See More

Key Turning Points

3rd Resistance Point 2.77
2nd Resistance Point 2.66
1st Resistance Point 2.57
Last Price 2.48
1st Support Level 2.37
2nd Support Level 2.26
3rd Support Level 2.17

See More

52-Week High 4.98
Fibonacci 61.8% 3.47
Fibonacci 50% 3.00
Fibonacci 38.2% 2.53
Last Price 2.48
52-Week Low 1.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar